PAR. SP, page-813

My back of the envelope calculations suggest we have more than enough funds for stage 2 of phase 3 based off the quarterly reporting over the months that include stage 1
of the phase 3.

Those quarterly reports were on Ave 20 million burn, BUT included the MPS 6 trial (now finished) and the 008 trial (now finished and other preclinical studies for adrenal and protocol review meetings.

Also, if you take the time to look at the primary outcome for phase 3 trial, of pain and function at day 56 we were statistically significant in 005 and 008

2mg dose will be fine….